Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1345P - Using social listening to understand stakeholder perceptions of the patient journey in lung cancer

Date

16 Sep 2021

Session

ePoster Display

Presenters

Ana Rodrigues

Citation

Annals of Oncology (2021) 32 (suppl_5): S949-S1039. 10.1016/annonc/annonc729

Authors

A.C.F. Rodrigues1, J. Chauhan2, A. Sagkriotis3, S. Aasaithambi2, M. Montrone4

Author affiliations

  • 1 Medical Oncology, Instituto Português de Oncologia do Porto Francisco Gentil, EPE, 4200-162 - Porto/PT
  • 2 Business Analytics, Novartis Healthcare Pvt. Ltd (H.A.), Hyderabad/IN
  • 3 Ore Medical Affairs, Novartis Pharma, Basel/CH
  • 4 Medical Thoracic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 - Bari/IT
More

Abstract 1345P

Background

Social media is widely used by multiple stakeholders to access and share health-related information and experiences. Lung cancer is the most common cancer globally, affecting the lives of >2 million patients. This observational study utilised a social listening approach to analyse social media trends and gain insights into stakeholder perceptions in lung cancer.

Methods

Data were collected retrospectively (June 2019–May 2020) from open-access blogs, forums, and social networking sites across 14 European countries. Conversations containing lung cancer and non-small cell lung cancer (NSCLC)-specific terms were extracted using social media aggregator tools. The information was filtered to a contextualised dataset by automated relevancy algorithms and manual review. Random sampling procedures generated the final dataset for analysis.

Results

Of 1360 conversations analysed, 42% were generated by patients/caregivers and 14% by healthcare professionals (HCPs). Most patients were 51-70 years old (∼50%) and 91% (n=550) had late-stage cancer. Treatment was the most discussed topic of the patient journey, followed by causes and diagnosis. While overall treatment sentiment was neutral, chemotherapy had the highest share of negativity (12% positive, 28% negative; n=318). Immunotherapy and targeted therapy were perceived more positively due to perceptions of longer survival outcomes with comparatively fewer side effects (47% positive, 9% negative; n=276 and 47% positive, 2% negative; n=139, respectively). The most mentioned clinical endpoints were ‘prolonged survival’ and ‘overall survival’ (47% and 30%, respectively; n=539). HCPs mostly used technical terms whereas patients and caregivers used colloquial terms such as ‘getting rid of cancer’. Exhaustion of treatment options and intolerable side effects led to treatment discontinuation; relapse, metastasis, and inefficacy were key factors for switching between treatments.

Conclusions

Social listening is a powerful tool to explore stakeholder perceptions and their key unmet needs, typically not available in published literature or databases, and provides HCPs with insight into the distress and doubts of patients and caregivers.

Clinical trial identification

Editorial acknowledgement

Medical editorial assistance was provided by Sara Henriques, of Chameleon Communications, London, UK, which was funded by Novartis, East Hanover, NJ, USA.

Legal entity responsible for the study

Novartis.

Funding

Novartis.

Disclosure

A.C.F. Rodrigues: Non-Financial Interests, Personal, Training: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: MSD; Non-Financial Interests, Personal, Advisory Board: BMS; Non-Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Non-Financial Interests, Personal, Advisory Board: Roche. J. Chauhan: Financial Interests, Personal, Full or part-time Employment: Novartis. A. Sagkriotis: Financial Interests, Personal, Full or part-time Employment: Novartis. S. Aasaithambi: Financial Interests, Personal, Full or part-time Employment: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings